Products for Research Use Only

WQ-C-401

CAT: 0804-HY-162888-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-162888-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
WQ-C-401 is an orally active platelet-derived growth factor receptor (PDGFR) inhibitor. WQ-C-401 inhibits cell proliferation by blocking PDGFR autophosphorylation in a concentration-dependent manner, with EC50 values of 3.5 nM for PDGFRα Y849 and 5.8 nM for PDGFRβ Y1021. Additionally, WQ-C-401 can inhibit PASMCs proliferation and migration by blocking PDGF-BB-induced ERK1/2 phosphorylation, reducing collagen I synthesis, and increasing α-SMA expression, thereby preventing pulmonary vascular remodeling. WQ-C-401 holds promise for research in the field of pulmonary arterial hypertension[1].
CAS Number
2376694-72-1
UNSPSC
12352211
Target
ERK; PDGFR
Type
Reference compound
Related Pathways
MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/wq-c-401.html
Purity
99.41
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC1=C(OC2CCN(C(C3=CN(C)C=N3)=O)CC2)C=C(NC(C4=CC=CC=C4)=O)C=C1
Molecular Formula
C24H26N4O3
Molecular Weight
418.49
References & Citations
[1]Huang W, et al. A novel PDGFR inhibitor WQ-C-401 prevents pulmonary vascular remodeling in rats with monocrotaline-induced pulmonary arterial hypertension. Exp Cell Res. 2024 Aug 1;441 (1) :114154.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PDGFRα; PDGFRβ